Last edition
News about "Perelman School of Medicine"
Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.
Perelman School Of Medicine | 09/02/2026 | By News Bureau | 130
Vasa Therapeutics Receives FDA IND Clearance to Advance Novel Small Molecule VS-041
Vasa Therapeutics plans to immediately initiate a phase-I (c) clinical trial in the US for participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
<br />
Perelman School Of Medicine | 15/10/2025 | By Dineshwori | 287
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy